- Akeso said its ivonescimab immunotherapy regimen outperformed AstraZeneca's Imfinzi plus chemotherapy in a head-to-head Phase 3 trial for advanced biliary tract cancer.
- The trial enrolled 682 patients, and Akeso said patients receiving its drug lived longer than patients on the AstraZeneca treatment.
- The study is ivonescimab's first positive Phase 3 result in gastrointestinal tumors, expanding the drug's solid-tumor development case.
- Akeso has not disclosed the trial's exact survival figures and expects to present them at a forthcoming conference.
Quotes
“The study marks the first positive phase-three study for ivonescimab in gastrointestinal tumours, potentially opening the door for the drug to be used in a “broader range of solid tumours”